Evolus, Inc. (NASDAQ:EOLS) Receives $16.00 Consensus Target Price from Brokerages

Evolus, Inc. (NASDAQ:EOLS) has been given a consensus recommendation of “Moderate Buy” by the six research firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $16.00.

A number of equities analysts have weighed in on the stock. Wall Street Zen lowered shares of Evolus from a “buy” rating to a “hold” rating in a research report on Sunday, March 15th. Weiss Ratings lowered shares of Evolus from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 29th. Finally, BTIG Research reiterated a “buy” rating and set a $13.00 target price on shares of Evolus in a research report on Wednesday, March 4th.

Insider Transactions at Evolus

In other Evolus news, insider Rui Avelar sold 29,996 shares of the stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $4.89, for a total transaction of $146,680.44. Following the completion of the transaction, the insider owned 430,542 shares in the company, valued at $2,105,350.38. This trade represents a 6.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider David Moatazedi sold 116,720 shares of the stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $4.89, for a total transaction of $570,760.80. Following the transaction, the insider owned 618,369 shares of the company’s stock, valued at $3,023,824.41. This represents a 15.88% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 163,504 shares of company stock valued at $797,184 in the last quarter. Company insiders own 5.00% of the company’s stock.

Institutional Investors Weigh In On Evolus

Institutional investors and hedge funds have recently modified their holdings of the company. Larson Financial Group LLC lifted its holdings in shares of Evolus by 136.6% in the fourth quarter. Larson Financial Group LLC now owns 4,914 shares of the company’s stock worth $33,000 after buying an additional 2,837 shares in the last quarter. Meeder Asset Management Inc. purchased a new stake in shares of Evolus in the fourth quarter worth about $34,000. Wexford Capital LP purchased a new stake in shares of Evolus in the third quarter worth about $37,000. Tower Research Capital LLC TRC lifted its holdings in shares of Evolus by 340.2% in the second quarter. Tower Research Capital LLC TRC now owns 7,364 shares of the company’s stock worth $68,000 after buying an additional 5,691 shares in the last quarter. Finally, Aquatic Capital Management LLC purchased a new stake in shares of Evolus in the third quarter worth about $48,000. 90.69% of the stock is owned by hedge funds and other institutional investors.

Evolus Stock Performance

EOLS opened at $6.73 on Wednesday. The firm has a market cap of $443.24 million, a P/E ratio of -10.04 and a beta of 1.34. The firm has a 50-day moving average of $5.71 and a 200 day moving average of $5.56. Evolus has a fifty-two week low of $3.86 and a fifty-two week high of $10.27.

Evolus (NASDAQ:EOLS) last issued its earnings results on Monday, May 4th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). The business had revenue of $73.14 million for the quarter, compared to analysts’ expectations of $72.52 million. During the same period in the previous year, the company earned ($0.30) EPS. Equities research analysts predict that Evolus will post -0.38 earnings per share for the current fiscal year.

About Evolus

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.